Skip to main content
. 2022 Mar 26;12(4):814. doi: 10.3390/diagnostics12040814

Figure 3.

Figure 3

Baseline and expected relative change in LDL-C control rate according to current and escalated therapies. NOS, statin-naïve; MIS, moderate-intensity statin; HIS, high-intensity statin; MIS + Ez, MiS combined with ezetimibe; HiS + Ez, HIS combined with ezetimibe; HbA1c, glycated hemoglobin.